Norethindrone Acetate Patch
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Transdermal
-
Intended Duration:
- Short-Acting
- Development Stage: Phase III
- Developer(s)/researcher(s): Allergan
Details
- API: Norethindrone
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Regimen: 3 Weeks Applied/1 Week Removed
- MPT: Not Potential MPT
Product Status
Does not appear to have continued development after 2013 denial of New Drug Application by US FDA
History
Phase III completed in 2012. NDA filed with US FDA in 2013. Received complete response letter from FDA in late 2013, indicating that product was not approved.